BlackRock Science (BSTZ) | Financial Analysis & Statements
BlackRock Science and Technology Trust II Small-cap Financial Services
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
1.8B
Total Liabilities
36.0M
Shareholders Equity
1.7B
Debt to Equity
0.02
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
BlackRock Science Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 316.1M | 274.2M | 282.2M | -1.3B | 250.7M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 1.1M | 748.9K | 1.3M | 1.4M | 1.8M |
| Other Operating Expenses | 651.0K | 1.1M | 909.1K | 409.9K | 326.3K |
| Total Operating Expenses | 1.8M | 1.9M | 2.2M | 1.8M | 2.2M |
| Operating Income | - | - | - | - | - |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 314.4M | 272.3M | 280.0M | -1.3B | 248.5M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 314.4M | 272.3M | 280.0M | -1.3B | 248.5M |
| Net Margin % | 99.4% | 99.3% | 99.2% | 0.0% | 99.1% |
| Key Metrics | |||||
| EBITDA | - | - | - | - | - |
| EPS (Basic) | - | $7.86 | $3.72 | $-16.99 | $3.18 |
| EPS (Diluted) | - | $7.86 | $3.72 | $-16.99 | $3.18 |
| Basic Shares Outstanding | - | 72314687 | 75258409 | 78637947 | 78160293 |
| Diluted Shares Outstanding | - | 72314687 | 75258409 | 78637947 | 78160293 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
BlackRock Science Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 722.1K | 12.7K | 0 | 1.4M | 209.8K |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | - | - | - | - | - |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | - | - | - | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | - | - | - | - | - |
| Total Assets | 1.8B | 1.7B | 1.7B | 1.5B | - |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 14.1M | - | 984.9K | 4.5M | 0 |
| Short-term Debt | - | - | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | - | - | - | - | - |
| Non-Current Liabilities | |||||
| Long-term Debt | - | 152.1K | 347.4K | - | - |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | - | - | - | - | - |
| Total Liabilities | 36.0M | 25.1M | 27.9M | 21.0M | - |
| Equity | |||||
| Common Stock | 942.7M | 1.0B | 1.2B | 1.4B | 1.5B |
| Retained Earnings | 774.4M | 644.3M | 425.3M | 152.3M | 1.5B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.7B | 1.7B | 1.6B | 1.5B | 3.0B |
| Key Metrics | |||||
| Total Debt | 0 | 152.1K | 347.4K | 0 | 0 |
| Working Capital | 0 | 0 | 0 | 0 | 0 |
Balance Sheet Composition
BlackRock Science Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 8.7M | 277.5M | 280.0M | -1.3B | 248.5M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -1.6M | 4.8M | 3.6M | -2.7M | 2.1M |
| Operating Cash Flow | 7.1M | 282.3M | 283.5M | -1.3B | 250.6M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - |
| Financing Activities | |||||
| Share Repurchases | -724.0M | -82.2M | -36.3M | -5.4M | - |
| Dividends Paid | -153.4M | -151.5M | -142.8M | -178.6M | -225.1M |
| Debt Issuance | - | - | - | 0 | 0 |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -877.4M | -233.8M | -179.1M | -184.0M | -225.1M |
| Free Cash Flow | 877.8M | 231.7M | 173.4M | 183.8M | 213.9M |
| Net Change in Cash | -870.3M | 48.5M | 104.5M | -1.5B | 25.5M |
Cash Flow Trend
BlackRock Science Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
5.48
Price to Sales
5.61
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
18.31%
Return on Assets
17.93%
Financial Health
Debt to Equity
0.00
Per Share Data
EPS (TTM)
$4.65
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BSTZ | 1.8B | 5.48 | - | 18.31% | 0.00% | 0.00 |
| BlackRock | 162.5B | 26.32 | 2.90 | 9.02% | 24.40% | 24.37 |
| Brookfield | 102.6B | 92.57 | 2.32 | 1.95% | 1.68% | 164.04 |
| Sixth Street | 1.8B | 10.27 | 1.10 | 10.61% | 37.97% | 108.43 |
| SRH Total Return | 1.7B | 10.03 | 0.78 | 8.01% | 536.79% | 10.04 |
| BlackRock Capital | 1.6B | 7.00 | - | 13.92% | 0.00% | 0.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.





